1. Home
  2. |Insights
  3. |Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Crowell & Moring Represents Third Rock Ventures in $108 Million Series C Financing for Terremoto Biosciences

Firm News | less than 1 min read | 04.15.26

Boston and San Francisco – April 15, 2026: Crowell & Moring represented investor Third Rock Ventures in the closing of a $108 million Series C financing round for Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines.  

Along with Third Rock, the financing included support from existing investors OrbiMed, Novo Holdings, and Cormorant Asset Management, LP, as well as from new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines. Proceeds from the financing will enable Terremoto to advance its selective AKT1 inhibitor programs through Phase 1 clinical development for patients with cancer and rare diseases such as hereditary hemorrhagic telangiectasia. 

The financing transaction was led by partner Kurt Machemer (Boston). 


Insights

Firm News | 2 min read | 10.22.26

Crowell & Moring Adds Veteran DOJ Health Care Litigator Jeff McSorley

WASHINGTON, D.C. – October 22, 2026: Crowell & Moring has added Jeff McSorley as a partner in its industry-leading Health Care Group in Washington, D.C. McSorley joins the firm from the U.S. Department of Justice (DOJ), where he served for the past decade as a senior trial counsel in the Civil Division’s Commercial Litigation Branch, Fraud Section....

View All Insights